StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sage Therapeutics (SAGE) PT Lowered to $58 at Stifel
February 24, 2022 10:19 AM
Stifel analyst Paul Matteis lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $58.00 (from $75.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Form S-8 Sage Therapeutics, Inc.
February 24, 2022 7:48 AM
Needham & Company Reiterates Buy Rating on Sage Therapeutics (SAGE), Analysts Expects no Impact on Stock From the Recent Earning Readout
February 24, 2022 7:26 AM
Form 10-K Sage Therapeutics, Inc. For: Dec 31
February 24, 2022 7:24 AM
Form 8-K Sage Therapeutics, Inc. For: Feb 24
February 24, 2022 6:46 AM
SAGE Therapeutics (SAGE) Tops Q4 EPS by 4c
February 24, 2022 6:39 AM
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
February 24, 2022 6:30 AM
